Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases
Identifieur interne : 001F60 ( Main/Merge ); précédent : 001F59; suivant : 001F61Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases
Auteurs : Kam Hon Yoon [Singapour]Source :
- APLAR Journal of Rheumatology [ 0219-0494 ] ; 2004-05.
English descriptors
- Teeft :
- Adjuvantinduced arthritis, Adverse events, Antiphospholipid syndrome, Aplar journal, Arthritis, Arthritis rheum, Azathioprine, Azathioprine steroids, Chinese woman, Conventional therapy, Creatinine, Cutaneous manifestations, Cutaneous vasculitis, Cyclosporin, Disease conditions, Gastrointestinal symptoms, Good response, Immunosuppressive agents, Interstitial lung disease, Liver dysfunction, Liver function test, Lupus, Lupus erythematosus, Lupus nephritis, Malar rash, Mycophenolate, Mycophenolate steroids, National university hospital, Nephritis, Normal range, Partial responders, Patient example, Pediatric patients, Period november, Prednisolone, Psoriatic, Psoriatic arthritis, Renal biopsy, Renal transplantation, Resistant diseases, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatology, Successful usage, Systemic lupus erythematosus, Tacrolimus, Topical tacrolimus.
Abstract
Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.
Url:
DOI: 10.1111/j.1479-8077.2004.00064.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000837
- to stream Istex, to step Curation: 000837
- to stream Istex, to step Checkpoint: 000D86
Links to Exploration step
ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title>
<author><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1479-8077.2004.00064.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000837</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000837</idno>
<idno type="wicri:Area/Istex/Curation">000837</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D86</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D86</idno>
<idno type="wicri:doubleKey">0219-0494:2004:Yoon K:successful:usage:of</idno>
<idno type="wicri:Area/Main/Merge">001F60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title>
<author><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Singapour</country>
<wicri:regionArea>Department of Medicine, National University Hospital</wicri:regionArea>
<wicri:noRegion>National University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Singapour</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">APLAR Journal of Rheumatology</title>
<title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title>
<idno type="ISSN">0219-0494</idno>
<idno type="eISSN">1479-8077</idno>
<imprint><biblScope unit="vol">7</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="44">44</biblScope>
<biblScope unit="page" to="48">48</biblScope>
<biblScope unit="page-count">5</biblScope>
<publisher>Blackwell Science Pty</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-05">2004-05</date>
</imprint>
<idno type="ISSN">0219-0494</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0219-0494</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvantinduced arthritis</term>
<term>Adverse events</term>
<term>Antiphospholipid syndrome</term>
<term>Aplar journal</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Azathioprine</term>
<term>Azathioprine steroids</term>
<term>Chinese woman</term>
<term>Conventional therapy</term>
<term>Creatinine</term>
<term>Cutaneous manifestations</term>
<term>Cutaneous vasculitis</term>
<term>Cyclosporin</term>
<term>Disease conditions</term>
<term>Gastrointestinal symptoms</term>
<term>Good response</term>
<term>Immunosuppressive agents</term>
<term>Interstitial lung disease</term>
<term>Liver dysfunction</term>
<term>Liver function test</term>
<term>Lupus</term>
<term>Lupus erythematosus</term>
<term>Lupus nephritis</term>
<term>Malar rash</term>
<term>Mycophenolate</term>
<term>Mycophenolate steroids</term>
<term>National university hospital</term>
<term>Nephritis</term>
<term>Normal range</term>
<term>Partial responders</term>
<term>Patient example</term>
<term>Pediatric patients</term>
<term>Period november</term>
<term>Prednisolone</term>
<term>Psoriatic</term>
<term>Psoriatic arthritis</term>
<term>Renal biopsy</term>
<term>Renal transplantation</term>
<term>Resistant diseases</term>
<term>Rheum</term>
<term>Rheumatic diseases</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatology</term>
<term>Successful usage</term>
<term>Systemic lupus erythematosus</term>
<term>Tacrolimus</term>
<term>Topical tacrolimus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001F60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1 |texte= Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases }}
This area was generated with Dilib version V0.6.33. |